Skip to content

CANDIS-II: Evaluation of the Cognitive-behavioral Treatment Programme CANDIS

Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II)

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00673647
Acronym
CANDIS-II
Enrollment
450
Registered
2008-05-07
Start date
2008-05-31
Completion date
2009-10-31
Last updated
2009-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis Use Disorders

Keywords

cannabis, dependence, marijuana, CBT, efficacy of CBT for cannabis use disorders

Brief summary

The purpose of this study is to evaluate the effectiveness of the cognitive-behavioral treatment program CANDIS among n=450 patients with cannabis use disorders in a mulicenter randomized-controlled clinical trial (n=11 outpatient treatment centers).

Interventions

10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.

Sponsors

Federal Ministry of Health
CollaboratorAMBIG
Technische Universität Dresden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* motivation to change cannabis use * age 16 or older * current (12 mth) regular cannabis use (at least 2 days a week) * informed consent to the study procedures and assessments

Exclusion criteria

* current alcohol or any illicit drug dependence syndrome according to DSM-IV other than due to cannabis * lifetime history of any psychotic disorder * current severe episode of Major depression * current panic-agoraphobic disorder (severe) * severe learning disability, brain damage or pervasive developmental disorder * currently acute suicidality * not fluent in german language * any other current treatment for cannabis use disorders

Design outcomes

Primary

MeasureTime frame
abstinence, defined as no evidence of cannabis use during the past 4 weeks as evidenced by self report and a negative urine screen; number of times a cannabis product was used in the past 4 weeks; retention rateat the end of treatment

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026